STAT Plus: With another trial failure, it may be time to revoke the approval of Acadia Pharma’s anti-psychosis drug By ADAM FEUERSTEIN

STAT Plus: With another trial failure, it may be time to revoke the approval of Acadia Pharma’s anti-psychosis drug

By ADAM FEUERSTEIN

The drug maker has run four randomized, placebo-controlled Phase 3 clinical trials of Nuplazid. Three of them have now failed

READ MORE